There’s huge excitement over the potential of gene therapy. But one-time treatments will only be successful if they provide long-term benefit for patients.
For BioMarin Pharmaceuticals (BMRN), soon-to-be-released data could offer indications about just how durable its gene therapy against hemophilia A could be. In June, the Novato, Calif.-based biotech is expected to disclose an update from a clinical trial that has followed the treatment of patients for three years.
Here are nine things to know about BioMarin’s gene therapy and this crucial measure of its long-term efficacy.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.